The National Medical Products Administration recently announced that according to the "Measures for the Classification Management of Prescription Drugs and Non prescription Drugs (Trial)" (formerly Order No. 10 of the National Medical Products Administration), after being organized by the National Medical Products Administration for verification and review, Linglian Flower Granules, Danzhi Xiaoyao Capsules, Qiushui Jianpi San, and Weishuning Tablets have been converted from prescription drugs to over-the-counter drugs. The announcement clearly states that relevant drug marketing license holders are required to file the revised instructions with the provincial drug regulatory department in accordance with the "Drug Registration Management Measures" and other relevant regulations before December 26, 2024, and promptly notify relevant medical institutions, drug trading enterprises, and other units of the revised instructions. Any other content of the prescription drug instruction manual beyond the prescribed content shall be executed in accordance with the original approval certificate. If the drug label involves relevant content, it should be revised together. Drugs produced from the date of supplementary application filing shall not continue to use the original drug instructions. (Lai Xin She)